A Phase 2, Two-Part (Open-Label Followed by Double-Blind) Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Adult Subjects With Moderate to Severe Major Depressive Disorder

Trial Profile

A Phase 2, Two-Part (Open-Label Followed by Double-Blind) Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Adult Subjects With Moderate to Severe Major Depressive Disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs SAGE 217 (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Sage Therapeutics
  • Most Recent Events

    • 17 Apr 2018 According to a SAGE Therapeutics media release, results from this study will be presented at the North American Society for Psychosocial Obstetrics and Gynecology (NASPOG) 2018.
    • 07 Feb 2018 According to a Sage Therapeutics media release, detailed results of this trial will be presented at an upcoming medical meeting.
    • 07 Feb 2018 According to a Sage Therapeutics media release, companyreceives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder.This regulatory decision was based on positive results from this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top